The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Ibrutinib for CLL within a population-based setting: a promising outlook
To determine the true impact of ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) within a population-based setting rather than a clinical trial setting, Lina van der Straten, PhD, of the Albert Schweitzer Hospital, Dordrect, Netherlands, outlines her collaboration with the Netherlands Cancer Registry, which allowed her to analyze patient survival over a prolonged period of time and draw some promising conclusions. Dr van der Straten presented these results at the 23rd Congress of the European Hematology Association (EHA) 2018 in Stockholm, Sweden.
